Price
$9.94
Decreased by -4.05%
Dollar Volume (20D)
2.02 M
ADR%
9.13
Earnings Report Date (estimate)
Apr 1, 24
Shares Float
7.48 M
Shares Outstanding
10.58 M
Shares Short
1.31 M
Market Cap.
105.16 M
Beta
1.65
Price / Earnings
N/A
20D Range
9.19 12
50D Range
9 22.49
200D Range
5.42 22.49
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 23 -1.63
Decreased by -75.27%
-1.09
Decreased by -49.54%
Aug 14, 23 -1.07
Increased by 0%
-1.14
Increased by +6.14%
Apr 3, 23 -0.38
Increased by +47.22%
-1.05
Increased by +63.81%
Mar 1, 23 -1.05
Decreased by -40%
-1.05
Nov 8, 22 -0.93
Decreased by -165.71%
-1.01
Increased by +7.92%
Aug 8, 22 -1.07
Decreased by -214.71%
-0.64
Decreased by -67.19%
May 4, 22 -0.72
Decreased by -56.52%
-0.58
Decreased by -24.14%
Mar 2, 22 -0.75
Decreased by -200%
-0.25
Decreased by -200%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-14.72 M
Decreased by -95.81%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-9.54 M
Decreased by -10.31%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-29.44 M
Decreased by -402.9%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-3.02 M
Increased by +48.93%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-7.52 M
Decreased by -163.87%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-8.65 M
Decreased by -242.47%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-5.85 M
Decreased by -82.98%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-5.91 M
Decreased by -246.98%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.